Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations

FDA approves the product well before Mylan's prediction of 2018.

StacksOfPapers_1200x675
This is not an image of an electronic application.

FDA beat Mylan NV's expectations for the approval of its Copaxone generic, even though it appears that the agency may have missed the target date that had been set.

Mylan surprised investors late Oct. 3 when it announced the approval of its substitutable generic of Teva Pharmaceutical Industries...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approvals

More from Product Reviews